Veracyte says phase 3 trial data validate Decipher Prostate Genomic Classifier

The company states: “Veracyte announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic Classifier in helping physicians make more informed treatment decisions for their patients with prostate cancer. The findings, presented at the 2023 American Society for Radiation Oncology Annual Meeting, suggest that the Decipher Prostate test can categorize more accurately risk of patients with clinically high-risk disease to help inform appropriate treatment. Data from a second study presented at ASTRO 2023 reveal there is minimal to moderate risk-score correlation between the gene expression signatures of three commercially available genomic classifiers, including the Decipher Prostate test. The study authors suggest that, given the lack of correlation seen in the cross-comparison, the level of evidence supporting each genomic test, per nationally recognized consensus guidelines, should drive utilization. The first study assessed the prognostic performance of the Decipher Prostate test among clinically high-risk patients with localized prostate cancer from the phase 3, randomized NRG RTOG 0521 clinical trial, who received radiation and two years of androgen deprivation therapy with or without docetaxel chemotherapy. Researchers generated Decipher Prostate test scores using biopsy samples from 183 patients, who were followed for a median of 9.9 years. Results show that only the Decipher Prostate risk score was independently associated with metastasis-free survival and distant metastasist, compared to standard risk factors including Gleason score, T-stage and prostate-specific antigen level. Additionally, patients with higher-risk Decipher Prostate genomic scores had worse DM compared to those with lower-risk scores. Cumulative DM at 10 years was 27% for those with higher-risk Decipher test scores vs. 9% for those with lower-risk Decipher test scores.”